Dow Up0.11% Nasdaq Up0.50%

Horizon Pharma, Inc. (HZNP)

-NasdaqGS
10.30 Up 0.14(1.38%) Aug 29, 4:00PM EDT
|After Hours : 10.30 Up 0.00 (0.01%) Aug 29, 4:45PM EDT
ProfileGet Profile for:
Horizon Pharma, Inc.
520 Lake Cook Road
Suite 520
Deerfield, IL 60015
United States - Map
Phone: 224-383-3000
Fax: 224-383-3001
Website: http://www.horizonpharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:436

Business Summary 

Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Its products include DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA and ankylosing spondylitis (AS). The company also offers RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma, Inc. was founded in 2005 and is headquartered in Deerfield, Illinois.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Horizon Pharma, Inc.

Corporate Governance 
Horizon Pharma, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Timothy P. Walbert , 47
Chairman, Chief Exec. Officer, Pres and Member of Bus. Devel. Committee
1.03M0.00
Mr. Robert J. De Vaere , 56
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
562.00K0.00
Dr. Jeffrey W. Sherman M.D., F.A.C.P., 59
Chief Medical Officer and Exec. VP of Devel., Regulatory Affairs & Manufacturing
595.00K0.00
Mr. Todd N. Smith , 44
Chief Commercial Officer and Exec. VP
564.00K0.00
Mr. Robert W. Metz ,
Sr. VP of Operations, HR and Gov. Affairs
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders